-+ 0.00%
-+ 0.00%
-+ 0.00%

China Accepts Junshi’s Subcutaneous Toripalimab Application for Urothelial Cancer Treatment

PUBT·10/29/2026 00:26:04
Listen to the news
China Accepts Junshi’s Subcutaneous Toripalimab Application for Urothelial Cancer Treatment
  • China's NMPA accepted Junshi Biosciences' supplemental application for subcutaneous toripalimab combined with disitamab vedotin.
  • The combination targets first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma.
  • Applications for the subcutaneous formulation now cover all 13 approved indications of intravenous toripalimab.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610282025OMX_____CNEWS_EN_GNW9855772_en) on October 29, 2026, and is solely responsible for the information contained therein.